These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

433 related items for PubMed ID: 31895102

  • 1. Tumor uptake and associated greater efficacy of anti-Her2 immunoliposome does not rely on Her2 expression status: study of a docetaxel-trastuzumab immunoliposome on Her2+ breast cancer model (SKBR3).
    Rodallec A, Sicard G, Giacometti S, Carre M, Maia T, Valette M, Bouquet F, Savina A, Lacarelle B, Ciccolini J, Fanciullino R.
    Anticancer Drugs; 2020 Jun; 31(5):463-472. PubMed ID: 31895102
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Docetaxel-trastuzumab stealth immunoliposome: development and in vitro proof of concept studies in breast cancer.
    Rodallec A, Brunel JM, Giacometti S, Maccario H, Correard F, Mas E, Orneto C, Savina A, Bouquet F, Lacarelle B, Ciccolini J, Fanciullino R.
    Int J Nanomedicine; 2018 Jun; 13():3451-3465. PubMed ID: 29950829
    [Abstract] [Full Text] [Related]

  • 4. Anti-HER2 immunoliposomes for co-delivery of paclitaxel and rapamycin for breast cancer therapy.
    Eloy JO, Petrilli R, Chesca DL, Saggioro FP, Lee RJ, Marchetti JM.
    Eur J Pharm Biopharm; 2017 Jun; 115():159-167. PubMed ID: 28257810
    [Abstract] [Full Text] [Related]

  • 5. Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery.
    Park JW, Hong K, Kirpotin DB, Colbern G, Shalaby R, Baselga J, Shao Y, Nielsen UB, Marks JD, Moore D, Papahadjopoulos D, Benz CC.
    Clin Cancer Res; 2002 Apr; 8(4):1172-81. PubMed ID: 11948130
    [Abstract] [Full Text] [Related]

  • 6. Positron-Emission Tomography of HER2-Positive Breast Cancer Xenografts in Mice with 89Zr-Labeled Trastuzumab-DM1: A Comparison with 89Zr-Labeled Trastuzumab.
    Al-Saden N, Lam K, Chan C, Reilly RM.
    Mol Pharm; 2018 Aug 06; 15(8):3383-3393. PubMed ID: 29957952
    [Abstract] [Full Text] [Related]

  • 7. Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial.
    Hurvitz SA, Martin M, Symmans WF, Jung KH, Huang CS, Thompson AM, Harbeck N, Valero V, Stroyakovskiy D, Wildiers H, Campone M, Boileau JF, Beckmann MW, Afenjar K, Fresco R, Helms HJ, Xu J, Lin YG, Sparano J, Slamon D.
    Lancet Oncol; 2018 Jan 06; 19(1):115-126. PubMed ID: 29175149
    [Abstract] [Full Text] [Related]

  • 8. Development and Evaluation of Tri-Functional Immunoliposomes for the Treatment of HER2 Positive Breast Cancer.
    Vaidya T, Straubinger RM, Ait-Oudhia S.
    Pharm Res; 2018 Mar 13; 35(5):95. PubMed ID: 29536232
    [Abstract] [Full Text] [Related]

  • 9. Trastuzumab uptake and its relation to efficacy in an animal model of HER2-positive breast cancer brain metastasis.
    Lewis Phillips GD, Nishimura MC, Lacap JA, Kharbanda S, Mai E, Tien J, Malesky K, Williams SP, Marik J, Phillips HS.
    Breast Cancer Res Treat; 2017 Aug 13; 164(3):581-591. PubMed ID: 28493046
    [Abstract] [Full Text] [Related]

  • 10. Enhanced antitumor activity of trastuzumab emtansine (T-DM1) in combination with pertuzumab in a HER2-positive gastric cancer model.
    Yamashita-Kashima Y, Shu S, Harada N, Fujimoto-Ouchi K.
    Oncol Rep; 2013 Sep 13; 30(3):1087-93. PubMed ID: 23783223
    [Abstract] [Full Text] [Related]

  • 11. Lapatinib and 17AAG reduce 89Zr-trastuzumab-F(ab')2 uptake in SKBR3 tumor xenografts.
    Oude Munnink TH, de Vries EG, Vedelaar SR, Timmer-Bosscha H, Schröder CP, Brouwers AH, Lub-de Hooge MN.
    Mol Pharm; 2012 Nov 05; 9(11):2995-3002. PubMed ID: 23003202
    [Abstract] [Full Text] [Related]

  • 12. Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models.
    Kirpotin DB, Drummond DC, Shao Y, Shalaby MR, Hong K, Nielsen UB, Marks JD, Benz CC, Park JW.
    Cancer Res; 2006 Jul 01; 66(13):6732-40. PubMed ID: 16818648
    [Abstract] [Full Text] [Related]

  • 13. Targeting of the HER2/HER3 signaling axis overcomes ligand-mediated resistance to trastuzumab in HER2-positive breast cancer.
    Watanabe S, Yonesaka K, Tanizaki J, Nonagase Y, Takegawa N, Haratani K, Kawakami H, Hayashi H, Takeda M, Tsurutani J, Nakagawa K.
    Cancer Med; 2019 Mar 01; 8(3):1258-1268. PubMed ID: 30701699
    [Abstract] [Full Text] [Related]

  • 14. Dual targeting of HER2-positive cancer with trastuzumab emtansine and pertuzumab: critical role for neuregulin blockade in antitumor response to combination therapy.
    Phillips GD, Fields CT, Li G, Dowbenko D, Schaefer G, Miller K, Andre F, Burris HA, Albain KS, Harbeck N, Dieras V, Crivellari D, Fang L, Guardino E, Olsen SR, Crocker LM, Sliwkowski MX.
    Clin Cancer Res; 2014 Jan 15; 20(2):456-68. PubMed ID: 24097864
    [Abstract] [Full Text] [Related]

  • 15. A randomized, 3-arm, neoadjuvant, phase 2 study comparing docetaxel + carboplatin + trastuzumab + pertuzumab (TCbHP), TCbHP followed by trastuzumab emtansine and pertuzumab (T-DM1+P), and T-DM1+P in HER2-positive primary breast cancer.
    Masuda N, Ohtani S, Takano T, Inoue K, Suzuki E, Nakamura R, Bando H, Ito Y, Ishida K, Yamanaka T, Kuroi K, Yasojima H, Kasai H, Takasuka T, Sakurai T, Kataoka TR, Morita S, Ohno S, Toi M.
    Breast Cancer Res Treat; 2020 Feb 15; 180(1):135-146. PubMed ID: 31953696
    [Abstract] [Full Text] [Related]

  • 16. Rapamycin-loaded Immunoliposomes Functionalized with Trastuzumab: A Strategy to Enhance Cytotoxicity to HER2-positive Breast Cancer Cells.
    Eloy JO, Petrilli R, Brueggemeier RW, Marchetti JM, Lee RJ.
    Anticancer Agents Med Chem; 2017 Feb 15; 17(1):48-56. PubMed ID: 27225450
    [Abstract] [Full Text] [Related]

  • 17. Synergistic antitumor efficacy against the EGFRvIII+HER2+ breast cancers by combining trastuzumab with anti-EGFRvIII antibody CH12.
    Xu W, Bi Y, Zhang J, Kong J, Jiang H, Tian M, Li K, Wang B, Chen C, Song F, Pan X, Shi B, Kong X, Gu J, Cai X, Li Z.
    Oncotarget; 2015 Nov 17; 6(36):38840-53. PubMed ID: 26474285
    [Abstract] [Full Text] [Related]

  • 18. Feasibility of tailored, selective and effective anticancer chemotherapy by direct injection of docetaxel-loaded immunoliposomes into Her2/neu positive gastric tumor xenografts.
    Yamamoto Y, Yoshida M, Sato M, Sato K, Kikuchi S, Sugishita H, Kuwabara J, Matsuno Y, Kojima Y, Morimoto M, Horiuchi A, Watanabe Y.
    Int J Oncol; 2011 Jan 17; 38(1):33-9. PubMed ID: 21109923
    [Abstract] [Full Text] [Related]

  • 19. Molecular targeting of HER2-overexpressing biliary tract cancer cells with trastuzumab emtansine, an antibody-cytotoxic drug conjugate.
    Yamashita-Kashima Y, Yoshimura Y, Fujimura T, Shu S, Yanagisawa M, Yorozu K, Furugaki K, Higuchi R, Shoda J, Harada N.
    Cancer Chemother Pharmacol; 2019 Apr 17; 83(4):659-671. PubMed ID: 30659304
    [Abstract] [Full Text] [Related]

  • 20. Tumor targeting using anti-her2 immunoliposomes.
    Park JW, Kirpotin DB, Hong K, Shalaby R, Shao Y, Nielsen UB, Marks JD, Papahadjopoulos D, Benz CC.
    J Control Release; 2001 Jul 06; 74(1-3):95-113. PubMed ID: 11489487
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.